Phencyclidine-induced locomotor activity in the rat is blocked by 6-hydroxydopamine lesion of the nucleus accumbens: Comparisons to other psychomotor stimulants

Edward D French, Guido Vantini

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

The present study was primarily designed to explore the relationship between phencyclidine(PCP)-induced hyperactivity and the mesolimbic dopamine (DA) system. In addition, the motor-activating and behavioral effects of amphetamine (1.5 mg/kg), SKF-10,047 (25.0 mg/kg), scopolamine (1.0 mg/kg), and caffeine (10.0 mg/kg) were also measured and compared to PCP action. While all compounds produced a moderate to large degree of hyperactivity with varying time courses for effect, gross behavioral observations indicated a greater similarity between PCP and SKF-10,047 than between any of the other drugs. Following bilateral 6-hydroxydopamine lesions of the nucleus accumbens the robust locomotor-stimulating action of 5 mg/kg PCP was significantly reduced. Such lesions also successfully prevented amphetamine- and SKF-10,047-induced hyperactivity, but not the behavioral activation produced by scopolamine or caffeine. These results suggest that PCP and SKF-10,047, like amphetamine, elicit locomotor activity through presynaptic DA mechanisms within the mesolimbic system.

Original languageEnglish (US)
Pages (from-to)83-88
Number of pages6
JournalPsychopharmacology
Volume82
Issue number1-2
DOIs
StatePublished - Dec 1983
Externally publishedYes

Fingerprint

Phencyclidine
Oxidopamine
Nucleus Accumbens
Amphetamine
Locomotion
Scopolamine Hydrobromide
Caffeine
Dopamine
Pharmaceutical Preparations

Keywords

  • Amphetamine
  • Caffeine
  • Locomotor activity
  • Nucleus accumbens
  • Phencyclidine (PCP)
  • Scopolamine
  • SKF-10,047

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{8807210640d34105bf113673dcfdf633,
title = "Phencyclidine-induced locomotor activity in the rat is blocked by 6-hydroxydopamine lesion of the nucleus accumbens: Comparisons to other psychomotor stimulants",
abstract = "The present study was primarily designed to explore the relationship between phencyclidine(PCP)-induced hyperactivity and the mesolimbic dopamine (DA) system. In addition, the motor-activating and behavioral effects of amphetamine (1.5 mg/kg), SKF-10,047 (25.0 mg/kg), scopolamine (1.0 mg/kg), and caffeine (10.0 mg/kg) were also measured and compared to PCP action. While all compounds produced a moderate to large degree of hyperactivity with varying time courses for effect, gross behavioral observations indicated a greater similarity between PCP and SKF-10,047 than between any of the other drugs. Following bilateral 6-hydroxydopamine lesions of the nucleus accumbens the robust locomotor-stimulating action of 5 mg/kg PCP was significantly reduced. Such lesions also successfully prevented amphetamine- and SKF-10,047-induced hyperactivity, but not the behavioral activation produced by scopolamine or caffeine. These results suggest that PCP and SKF-10,047, like amphetamine, elicit locomotor activity through presynaptic DA mechanisms within the mesolimbic system.",
keywords = "Amphetamine, Caffeine, Locomotor activity, Nucleus accumbens, Phencyclidine (PCP), Scopolamine, SKF-10,047",
author = "French, {Edward D} and Guido Vantini",
year = "1983",
month = "12",
doi = "10.1007/BF00426386",
language = "English (US)",
volume = "82",
pages = "83--88",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "1-2",

}

TY - JOUR

T1 - Phencyclidine-induced locomotor activity in the rat is blocked by 6-hydroxydopamine lesion of the nucleus accumbens

T2 - Comparisons to other psychomotor stimulants

AU - French, Edward D

AU - Vantini, Guido

PY - 1983/12

Y1 - 1983/12

N2 - The present study was primarily designed to explore the relationship between phencyclidine(PCP)-induced hyperactivity and the mesolimbic dopamine (DA) system. In addition, the motor-activating and behavioral effects of amphetamine (1.5 mg/kg), SKF-10,047 (25.0 mg/kg), scopolamine (1.0 mg/kg), and caffeine (10.0 mg/kg) were also measured and compared to PCP action. While all compounds produced a moderate to large degree of hyperactivity with varying time courses for effect, gross behavioral observations indicated a greater similarity between PCP and SKF-10,047 than between any of the other drugs. Following bilateral 6-hydroxydopamine lesions of the nucleus accumbens the robust locomotor-stimulating action of 5 mg/kg PCP was significantly reduced. Such lesions also successfully prevented amphetamine- and SKF-10,047-induced hyperactivity, but not the behavioral activation produced by scopolamine or caffeine. These results suggest that PCP and SKF-10,047, like amphetamine, elicit locomotor activity through presynaptic DA mechanisms within the mesolimbic system.

AB - The present study was primarily designed to explore the relationship between phencyclidine(PCP)-induced hyperactivity and the mesolimbic dopamine (DA) system. In addition, the motor-activating and behavioral effects of amphetamine (1.5 mg/kg), SKF-10,047 (25.0 mg/kg), scopolamine (1.0 mg/kg), and caffeine (10.0 mg/kg) were also measured and compared to PCP action. While all compounds produced a moderate to large degree of hyperactivity with varying time courses for effect, gross behavioral observations indicated a greater similarity between PCP and SKF-10,047 than between any of the other drugs. Following bilateral 6-hydroxydopamine lesions of the nucleus accumbens the robust locomotor-stimulating action of 5 mg/kg PCP was significantly reduced. Such lesions also successfully prevented amphetamine- and SKF-10,047-induced hyperactivity, but not the behavioral activation produced by scopolamine or caffeine. These results suggest that PCP and SKF-10,047, like amphetamine, elicit locomotor activity through presynaptic DA mechanisms within the mesolimbic system.

KW - Amphetamine

KW - Caffeine

KW - Locomotor activity

KW - Nucleus accumbens

KW - Phencyclidine (PCP)

KW - Scopolamine

KW - SKF-10,047

UR - http://www.scopus.com/inward/record.url?scp=0021335494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021335494&partnerID=8YFLogxK

U2 - 10.1007/BF00426386

DO - 10.1007/BF00426386

M3 - Article

C2 - 6141586

AN - SCOPUS:0021335494

VL - 82

SP - 83

EP - 88

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 1-2

ER -